1. Home
  2. /
  3. Venture Capital
  4. /
  5. Mablink Bioscience Enters an...

News / Venture Capital

Mablink Bioscience Enters an Agreement to be Acquired by Lilly

19 October 2023
The pending acquisition reects the potential of Mablink’s existing pipeline and proprietary PSARLink™ technology for development of additional drug conjugates. Lyon, France – October 18, 2023 – Mablink Bioscience (“Mablink”), a pre-clinical biotechnology company pioneering the development of next-generation antibody-drug conjugates (ADCs) via its PSARLink™ proprietary platform, today announced an agreement to be acquired by Eli Lilly and Company (“Lilly”).

Download

Press Release
Download

Related News

arrow-up-right
arrow-up-right
arrow-up-right